Illinois Municipal Retirement Fund lifted its stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 2.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,014 shares of the biotechnology company’s stock after purchasing an additional 972 shares during the period. Illinois Municipal Retirement Fund’s holdings in United Therapeutics were worth $21,683,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of UTHR. Toth Financial Advisory Corp lifted its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the second quarter worth about $30,000. Gen Wealth Partners Inc bought a new position in shares of United Therapeutics in the third quarter worth about $34,000. Caitlin John LLC bought a new position in shares of United Therapeutics in the second quarter worth about $37,000. Finally, International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the period. 94.08% of the stock is owned by institutional investors.
Analysts Set New Price Targets
UTHR has been the subject of a number of recent research reports. Royal Bank Of Canada boosted their price objective on United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Leerink Partners raised their target price on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday, October 19th. Raymond James Financial set a $720.00 price target on shares of United Therapeutics in a report on Wednesday, November 4th. HC Wainwright began coverage on shares of United Therapeutics in a research report on Monday. They issued a “buy” rating and a $660.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $676.40.
Check Out Our Latest Analysis on UTHR
Trending Headlines about United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, implying roughly 12% upside from the cited share price. HC Wainwright ratings
- Neutral Sentiment: The company announced participation in November investor conferences, giving investors an opportunity to hear updates but not signaling a specific business development. Investor conference announcement
- Neutral Sentiment: A report listed short interest at zero shares. That figure suggests no reported short position, but offers little clear directional signal for the stock.
- Negative Sentiment: CEO Martine Rothblatt sold shares in multiple transactions on November 6 and 9, while director Christopher Patusky also sold shares on November 9. Insider sales can raise concern about sentiment, though they do not necessarily indicate a change in the company’s outlook. SEC filing
Insiders Place Their Bets
In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $511.09, for a total value of $4,855,355.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $165,819,572.87. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 412,238 shares of company stock valued at $220,071,746. Corporate insiders own 8.60% of the company’s stock.
United Therapeutics Stock Up 1.1%
Shares of United Therapeutics stock opened at $588.61 on Wednesday. The stock’s 50-day simple moving average is $536.90 and its 200-day simple moving average is $534.57. United Therapeutics Corporation has a 52 week low of $449.58 and a 52 week high of $614.23. The company has a market capitalization of $25.07 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 3.97 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). The business had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $7.16 EPS. On average, equities analysts expect that United Therapeutics Corporation will post 24.47 earnings per share for the current year.
United Therapeutics declared that its Board of Directors has authorized a share buyback program on Thursday, October 22nd that authorizes the company to repurchase $2 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 8.3% of its shares through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.
United Therapeutics Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Articles
- Five stocks we like better than United Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
